NicOx : hopes for the Alzheimer's Disease

NicOx, the start-up of Sophia has made public new encouraging pre-clinical results, obtained thanks to its drug NCX-2216 for the treatment of Alzheimer's Disease. A research carried out by the University of Arizona has proved that this medicine can be efficient in moderating the neuroinflammation on animals as well as the protection of cholinergic neurons. 'The new results of Professor Wenk, as it was announced in the press release, could allow to create an efficient therapy, moderating significantly the progression of demantia in Alzheimer's Disease. As a result, Michele Garufi, NicOx's CEO has decided to extend R&D works on this compound and to search pharmaceutical partners for this programme.